Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has received order on January 21, 2016 under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transaction of the company to sell Ranbaxy’s two CNS divisions to Strides Shasun (formerly known as Strides Arcolab). With this approval, all necessary regulatory approvals have been obtained.

Last year in September, the company was in process of selling Ranbaxy’s two divisions in Central Nervous System (CNS) segment in India to Strides Shasun for Rs 165 crore. The pharma major and Strides have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.